Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)

O. Illini, H. Fabikan, A. Swalduz, D. Krenbek, A. Vikstrom, M. Schumacher, E. Dudnik, M. Studnicka, R. Ohman, R. Wurm, L. Wannesson, N. Peled, W. Kian, J. Bar, S. Daher, A. Addeo, O. Rotem, G. Pall, A. Zer, A. SaadT. Cufer, H. G. Sorotsky, S. M. S. Hashemi, K. Mohorcic, R. Stoff, Y. Rovitsky, S. Keren-Rosenberg, T. Winder, C. Weinlinger, A. Valipour, M. J. Hochmair

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)S460-S460
JournalJournal of thoracic oncology
Issue number9
Publication statusPublished - Sept 2022


  • MET exon 14 skipping mutation
  • capmatinib
  • targeted therapy

Cite this